National Study on Local Ablative Therapy for Patients With Oligometastatic Non-Hematological Cancer Assessing Surgery, Radiotherapy, Thermal Ablation, and Electroporation Treatments

What this Trial Is About

Researchers are studying patients with oligometastatic disease OMD from any non-blood cancer to understand how local treatments aimed at targeting metastases work over time. The purpose is to track the success duration of various local ablative therapies LAT such as surgery, radiotherapy, thermal ablation, and electroporation across different cancer types and metastatic sites. This national, multicenter study combines both observational and interventional approaches to assess treatment impact and patient outcomes. Patients receive local ablative therapy using one or more methods including surgical removal of metastases, stereotactic radiotherapy, thermal ablation, or electroporation. Treatment decisions are made by a multidisciplinary team and may involve standard or non-standard LAT based on clinical relevance. The study includes an observational group treated according to standard care guidelines and an interventional group receiving non-standard LAT. Patients may undergo multiple LAT treatments if their disease remains suitable for such interventions. Participants are followed over time with regular assessments every 3 to 6 months for up to 5 years or longer. Evaluations include imaging scans and clinical reviews to measure time until LAT strategy failure, progression-free survival, overall survival, local and distant tumor control, and treatment side effects. Safety is closely monitored with toxicity reports collected every 3 months for the first 2 years. The study continues patient follow-up until death or withdrawal, aiming to better understand long-term outcomes and improve treatment planning for OMD.

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease